Dr. Tzachanis on the Likelihood of Cure With CAR T-Cell Therapy in Lymphoma

Video

Dimitrios Tzachanis, MD, PhD, discusses the likelihood of cure with CAR-T cell therapy in lymphoma.

Dimitrios Tzachanis, MD, PhD, hematologist/medical oncologist and assistant professor of medicine, University of California, San Diego Health, discusses the likelihood of cure with CAR-T cell therapy in lymphoma.

According to Tzachanis, it is difficult to definitively say that a patient is cured from their cancer.

However, since diffuse large B-cell lymphoma and acute lymphoblastic leukemia are fast-growing diseases, patients who derive at least 2-year remissions with CAR T-cell therapy may be effectively cured, concludes Tzachanis.

Recent Videos
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Related Content
© 2025 MJH Life Sciences

All rights reserved.